---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-020123"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T14:58:59.854912+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q4 revenue $1.7M, cash $316M; FT522 first patient dosed, FT825 study initiated

## Summary
- Cash and investments $316.2M at Dec 31, 2023; Q4 GAAP operating expenses $49.8M (R&D $31.8M, G&A $17.9M).
- Revenue $1.7M from Ono collaboration preclinical activities; no product revenue.
- FT522 (CAR NK) first patient treated; Phase 1 includes ADR technology, regimen with/without chemo conditioning.
- FT825/ONO-8250 (CAR T) Phase 1 started for solid tumors; HER2-targeted with novel synthetic controls.
- CIRM awarded $7.9M grant for FT819 Phase 1 SLE study; study start-up at multiple U.S. sites.

## SEC filing metadata
- accession: 0000950170-24-020123
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017024020123/0000950170-24-020123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017024020123/fate-20240226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-020123
- JSON: https://secwatch.observer/filing/0000950170-24-020123.json
- Plain text: https://secwatch.observer/filing/0000950170-24-020123.txt

## Key facts
- Earnings Releases
  FATE THERAPEUTICS INC reported financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On February 26, 2024, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017024020123/0000950170-24-020123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.